Knowledge, attitudes and practices about Cannabis light among a sample of Italian undergraduates
Keywords:
Cannabis light; tetrahydrocannabinol; cannabidiol; drug; undergraduatesAbstract
Background. Over the past few years, the market for “cannabis light”, substance with a tetrahydrocannabinol content of less than 0.6% (according to Italian law), has become established. The aim of the present study was to evaluate knowledge, attitudes and practices about cannabis light products among a sample of Italian undergraduates.
Methods. This cross-sectional study was conducted in the academic year 2023/2024. Participants completed an anonymous questionnaire regarding socio-demographic data, knowledge about cannabis light products and their effects, attitudes and practices related to these products. Responses on knowledge were aggregated into a dichotomous variable (“good knowledge” and “poor knowledge”). A multivariate analysis was performed on the knowledge variable using age, gender, type of secondary school attended, tobacco use and having used cannabis light-containing products as independent variables.
Results. Only 24.6% of the sample stated that they had used a product containing cannabis light at least once and 70.1% showed poor knowledge about such products. Students from technical or vocational secondary schools were significantly less likely to have good knowledge (OR=0.4; 95%CI=0.19-0.88). In contrast, those who had used these products at least once were more likely to have good knowledge (OR=4.8; 95%CI=2.84-8.25).
Conclusions. Despite the increasing popularity of cannabis light products, the level of knowledge among university students remains low. Therefore, interventions are needed to fill knowledge gaps about these products and to guarantee their informed use.
References
1. Hindley G, Beck K, Borgan F, Ginestet CE, McCutcheon R, Kleinloog D, et al. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. Lancet Psychiatry. 2020 Apr;7(4):344-353. doi: 10.1016/S2215-0366(20)30074-2. PMID: 32197092.
2. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: Trends and Developments. European Drug Report. 2019 Jun 6; Available from: https://www.emcdda.europa.eu/publications/edr/trends-developments/2019_en [Last accessed: 2025 Feb 20].
3. Chayasirisobhon S. Mechanisms of Action and Pharmacokinetics of Cannabis. Perm J. 2020 Dec;25:1-3. doi: 10.7812/TPP/19.200. PMID: 33635755.
4. Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018 Nov;84(11):2477-2482. doi: 10.1111/bcp.13710. PMID: 30001569.
5. Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Cannabidiol Adverse Effects and Toxicity. Curr Neuropharmacol. 2019;17(10):974-989. doi: 10.2174/1570159X17666190603171901. PMID: 31161980.
6. FDA. FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy. FDA News Release. 2018 Jun 25; Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms [Last accessed: 2025 Feb 20].
7. Mayor S. WHO proposes rescheduling cannabis to allow medical applications. BMJ. 2019 Feb 5;364:l574. doi: 10.1136/bmj.l574. PMID: 30723076.
8. The Editors of ProCon. Medical Marijuana. Should Medical Marijuana Be Legal? Encyclopedia Britannica. 2025 Feb 10; Available from: https://www.britannica.com/procon/medical-marijuana-debate [Last accessed: 2025 Feb 20].
9. Mead A. The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law. Epilepsy Behav. 2017 May;70(Pt B):288-291. doi: 10.1016/j.yebeh.2016.11.021. PMID: 28169144.
10. Legge n. 242, 2016 Dec 2. Disposizioni per la promozione della coltivazione e della filiera agroindustriale della canapa. Gazzetta Ufficiale della Repubblica Italiana. 2016 Dec 30; Available from: https://www.gazzettaufficiale.it/eli/id/2016/12/30/16G00258/sg [Last accessed: 2025 Feb 20].
11. EUR-Lex. Council Directive 2002/53/EC of 13 June 2002 on the common catalogue of varieties of agricultural plant species. Official Journal L 193. 2002 Jul 20; Available from: EUR-Lex - 32002L0053 - EN - EUR-Lex (europa.eu) [Last accessed: 2025 Feb 20].
12. Romeo A. Per la cannabis in Italia un giro d’affari potenziale di 30 miliardi. Il Sole 24 ORE. 2019 Dec 13; Available from: https://www.ilsole24ore.com/art/per-cannabis-italia-girod-affari-potenziale-30-miliardi-ACSDpK5 [Last accessed: 2025 Feb 20].
13. Wheeler M, Merten JW, Gordon BT, Hamadi H. CBD (Cannabidiol) Product Attitudes, Knowledge, and Use Among Young Adults. Subst Use Misuse. 2020 Feb 24;55(7):1138-1145. doi: 10.1080/10826084.2020.1729201. PMID: 32093530.
14. Corroon J, Phillips JA. A Cross-Sectional Study of Cannabidiol Users. Cannabis Cannabinoid Res. 2018 Jul 1;3(1):152-161. doi: 10.1089/can.2018.0006. PMID: 30014038.
15. Stronati C. The design of upper secondary education across OECD countries: Managing choice, coherence and specialization. OECD. 2023 APR 3; Available from: https://one.oecd.org/document/EDU/WKP(2023)3/en/pdf [Last accessed: 2025 Feb 20].
16. Geppert J, Lietzow J, Hessel-Pras S, Kirsch F, Schäfer B, Sachse B. Usage and health perception of cannabidiol-containing products among the population in Germany: a descriptive study conducted in 2020 and 2021. BMC Public Health. 2023 Nov 23;23(1):2318. doi: 10.1186/s12889-023-17142-0. PMID: 37996800.
17. Casanova C, Ramier C, Fortin D, Carrieri P, Mancini J, Barré T. Cannabidiol use and perceptions in France: a national survey. BMC Public Health. 2022 Aug 29;22(1):1628. doi: 10.1186/s12889-022-14057-0. PMID: 36038869.
18. Lachenmeier DW, Habel S, Fischer B, Herbi F, Zerbe Y, Bock V, et al. Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination? F1000Res. 2019 Aug 8;8:1394. doi: 10.12688/f1000research.19931.7. PMID: 32117565.
19. Protano C, Valeriani F, Marotta D, Bargellini A, Bianco A, Caggiano G, et al. Assessing Undergraduates’ Perception of Risks Related to Body Art in Italy: The SUPeRBA Multicenter Cross-Sectional Study. Int J Environ Res Public Health. 2021 Sep 1;18(17):9233. doi: 10.3390/ijerph18179233. PMID: 34501822.
20. Felnhofer A, Kothgassner OD, Stoll A, Klier C. Knowledge about and attitudes towards medical cannabis among Austrian university students. Complement Ther Med. 2021 May;58:102700. doi: 10.1016/j.ctim.2021.102700. PMID: 33677020.
21. Weisman JM, Rodríguez M. A systematic review of medical students’ and professionals’ attitudes and knowledge regarding medical cannabis. J Cannabis Res. 2021 Oct 12;3(1):47. doi: 10.1186/s42238-021-00100-1. PMID: 34641976.
22. Botella-Juan L, Amezcua-Prieto C, Morales-Suarez-Varela MM, Mateos-Campos R, Ayán-Pérez C, Molina AJ, et al. Impact of the COVID-19 Pandemic on the Evolution of Prevalence and Patterns of Cannabis Use among First-Year University Students in Spain—UniHcos Project. Int J Environ. Res Public Health. 2022 Sep 14;19(18):11577. doi: 10.3390/ijerph191811577. PMID: 36141846.
23. Alves R, Precioso J, Becoña E. llicit Drug Use among College Students: The Importance of Knowledge about Drugs, Live at Home and Peer Influence. J Psychoactive Drugs. 2021 Sep-Oct;53(4):329–338. doi: 10.1080/02791072.2020.1865592. PMID: 33382024.
24. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2021: Trends and Developments. European Drug Report. 2021 Jun 9; Available from: https://op.europa.eu/en/publication-detail/-/publication/a3dd1033-fd56-11ea-b44f-01aa75ed71a1/language-en [Last accessed: 2025 Feb 20].
25. Cuttler C, Spradlin A, McLaughlin RJ. A naturalistic examination of the perceived effects of cannabis on negative affect. J Affect Disord. 2018 Aug 1;235:198-205. doi: 10.1016/j.jad.2018.04.054. PMID: 29656267.
26. Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Front Immunol. 2018 Sep 21;9:2009. doi: 10.3389/fimmu.2018.02009. PMID: 30298064.
27. Sholler DJ, Schoene L, Spindle TR. Therapeutic Efficacy of Cannabidiol (CBD): A Review of the Evidence from Clinical Trials and Human Laboratory Studies. Curr Addict Rep. 2020 Sep;7(3):405-412. doi: 10.1007/s40429-020-00326-8. PMID: 33585159.
28. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010 Feb;35(3):764-774. doi: 10.1038/npp.2009.184. PMID: 19924114.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Daniela Marotta, Salvatore Borzì, Angela Pozzoli, Katia Vitale, Sergio Gazzanelli, Matteo Vitali, Carmela Protano (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.